Mainz Biomed NV has launched the eAArly DETECT 2 feasibility study, aimed at validating previous results on advanced adenomas using a large population of approximately 2,000 average risk patients.

Biomed Industries, Inc. Presents Breakthrough Phase 2 Results of NA-931, a First-in-Class Oral Quadruple Agonist for the Treatment of Obesity , at ADA 2025 NA-931's Phase 2 results highlight its ...

Mainz Biomed N.V., a molecular genetics diagnostic company, announced significant achievements in the first quarter of 2025 and provided an update on its progress toward FDA premarket approval. The ...

NA-831 is the only drug to date that has halted Alzheimer’s disease progression. Combining it with existing drugs like Donanemab could optimize therapeutic efficacy and reduce serious side effects.” — ...